Weight Navigation Program Boosts Use of Weight Management Treatments
By Elana Gotkine HealthDay Reporter
FRIDAY, May 31, 2024 -- A primary care-based weight navigation program (WNP) is feasible and associated with greater use of weight management treatments (WMT) and weight loss, according to a study published online May 21 in JAMA Network Open.
Dina H. Griauzde, M.D., from the University of Michigan Medical School in Ann Arbor, and colleagues examined the association of a primary care-based WNP with WMT use and weight loss in a cohort study. Participants were adults with obesity and one or more weight-related condition; data were included for 264 patients (132 WNP patients and 132 matched controls).
The researchers found that in a difference-in-differences analysis, WNP patients lost 4.9 kg more than matched controls, had 4.4 percent greater weight loss, and were more likely to achieve 5 percent or more and 10 percent or more weight loss (odds ratios, 2.90 and 7.19, respectively). Patients in the WNP group were referred to WMTs at higher rates, including bariatric surgery (18.9 versus 9.1 percent), a low-calorie meal replacement program (16.7 versus 3.8 percent), and a Mediterranean-style diet and activity program (10.6 versus 1.5 percent). No differences were seen between the groups in antiobesity medication prescribing.
"The WNP is a promising model to improve obesity treatment in primary care settings and warrants rigorous evaluation in a large-scale randomized clinical trial with longer-term assessment of outcomes and determinants of implementation," the authors write.
Several authors disclosed ties to industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2024
Read this next
In Pediatric Leukemia, Survival Linked to Duration of Overweight, Obesity
TUESDAY, May 20, 2025 -- For children with acute lymphoblastic leukemia (ALL), longer duration of overweight or obesity is associated with lower overall and event-free survival...
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...
Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery
THURSDAY, May 15, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.